ONWARD Medical N.V. financials
ONWARD Medical N.V.
9845007A2CC4C8BFSB80 | Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | €5.4M | €1.7M |
| Cost of sales | €1.0M | €22.0K |
| Gross profit | €4.4M | €1.7M |
| Operating expenses | €45.3M | €36.6M |
| Operating profit (EBIT) | -€40.9M | -€34.9M |
| Net finance income / (cost) | -€560.0K | -€903.0K |
| Finance costs | €2.3M | €2.1M |
| Profit before tax | -€41.5M | -€35.8M |
| Income tax expense | €311.0K | -€40.0K |
| Profit for the year | -€41.8M | -€35.7M |
| — attributable to owners | -€41.8M | -€35.7M |
| Total comprehensive income | -€43.3M | -€36.9M |
| Per share | ||
| Basic EPS | €-0.90 | €-0.80 |
| Diluted EPS | €-0.90 | €-0.80 |
| Free cash flow / share | €-0.85 | €-0.71 |
| Cash flow statement | ||
| Net cash from operating activities | -€39.1M | -€31.8M |
| Income taxes paid | €257.0K | €167.0K |
| Net cash from investing activities | -€432.0K | -€150.0K |
| Purchase of PP&E (capex) | €432.0K | €150.0K |
| Net cash from financing activities | €47.3M | €62.6M |
| Proceeds from borrowings | €0 | €14.1M |
| Repayments of borrowings | €0 | €15.3M |
| Lease liability payments | €600.0K | €560.0K |
| Net change in cash | €7.8M | €30.6M |
| Balance sheet | ||
| Total assets | €84.6M | €76.1M |
| Non-current assets | €10.5M | €12.5M |
| Property, plant & equipment | €534.0K | €471.0K |
| Right-of-use assets | €551.0K | €1.1M |
| Intangible assets & goodwill | €8.7M | €10.4M |
| Current assets | €74.1M | €63.6M |
| Inventories | €803.0K | €102.0K |
| Trade & other receivables | €1.2M | €160.0K |
| Cash & equivalents | €68.1M | €60.0M |
| — attributable to owners | €55.3M | €48.1M |
| Non-current liabilities | €18.1M | €18.8M |
| Long-term borrowings | €13.1M | €14.0M |
| Lease liabilities (non-current) | €53.0K | €518.0K |
| Current liabilities | €11.1M | €9.3M |
| Lease liabilities (current) | €538.0K | €597.0K |
| Deferred tax liabilities | €347.0K | €303.0K |
| Derived metrics | ||
| Free cash flow | -€39.5M | -€31.9M |
| Operating margin | -755.7% | -2004.7% |
| Net margin | -771.8% | -2054.3% |
| Return on equity | -75.5% | -74.3% |
| Cash conversion ratio | 0.93× | 0.89× |
| Capex coverage | -90.43× | -211.75× |
| Other reported items | ||
| Adjustments For Decrease Increase In Trade and Other Receivables | -€2.9M | -€1.9M |
| Adjustments For Depreciation and Amortisation Expense and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €1.4M | €898.0K |
| Adjustments For Finance Income Cost | -€560.0K | -€902.0K |
| Adjustments For Increase Decrease In Employee Benefit Liabilities | €49.0K | €126.0K |
| Adjustments For Increase Decrease In Trade and Other Payables | €2.0M | €2.3M |
| Adjustments For Sharebased Payments | €2.6M | €2.7M |
| Comprehensive Income Attributable To Owners of Parent | -€43.3M | -€36.9M |
| Current Prepayments and Other Current Assets | €3.6M | €3.2M |
| Current Tax Liabilities Current | €179.0K | €200.0K |
| Current Value Added Tax Receivables | €381.0K | €125.0K |
| Deferred Tax Assets | €659.0K | €568.0K |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | €220.0K | -€372.0K |
| Equity and Liabilities | €84.6M | €76.1M |
| Finance Income | €1.7M | €1.2M |
| General and Administrative Expense | €16.8M | €12.6M |
| Increase Decrease Through Exercise of Options | €337.0K | — |
| Increase Decrease Through Sharebased Payment Transactions | €2.6M | €2.7M |
| Interest Paid Classified As Operating Activities | €1.7M | €1.7M |
| Interest Received Classified As Operating Activities | €496.0K | €686.0K |
| Issue of Equity | €50.9M | €70.0M |
| Issued Capital | €6.7M | €5.4M |
| Noncurrent Recognised Liabilities Defined Benefit Plan | €4.7M | €4.0M |
| Other Adjustments For Noncash Items | €148.0K | €143.0K |
| Other Comprehensive Income | -€1.5M | -€1.1M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -€1.0M | €434.0K |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | -€491.0K | -€1.6M |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | -€1.0M | €434.0K |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | -€491.0K | -€1.6M |
| Other Current Financial Liabilities | €370.0K | €437.0K |
| Other Current Payables | €6.9M | €6.8M |
| Other Reserves | €6.8M | €6.8M |
| Payments For Share Issue Costs | €3.2M | €5.7M |
| Proceeds From Exercise of Options | €337.0K | €0 |
| Proceeds From Issuing Shares | €50.9M | €70.0M |
| Retained Earnings | -€222.6M | -€181.8M |
| Revenue From Contracts With Customers | €3.7M | €77.0K |
| Revenue From Government Grants | €1.7M | €1.7M |
| Sales and Marketing Expense | €8.1M | €3.4M |
| Share Issue Related Cost | €3.2M | €5.7M |
| Share Premium | €264.4M | €217.8M |
| Trade and Other Current Payables To Related Parties | €51.0K | €0 |
| Trade and Other Current Payables To Trade Suppliers | €3.1M | €1.3M |
| Trade and Other Current Receivables Due From Related Parties | €0 | €36.0K |
Every line item above is a fact tagged in ONWARD Medical N.V.'s annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.